Float Short %

1.61

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.51

Price

1.77

Target Price

8.17

Analyst Recom

Performance Q

Relative Volume

1.46

Beta

1.45

Ticker: MRKR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-05-08	MRKR	1.28	N/A	N/A	0
2025-05-09	MRKR	1.16	N/A	N/A	0
2025-05-12	MRKR	1.14	N/A	N/A	0
2025-05-13	MRKR	1.12	N/A	N/A	0
2025-05-14	MRKR	1.125	N/A	N/A	0
2025-05-15	MRKR	1.11	N/A	N/A	0
2025-05-16	MRKR	1.11	N/A	N/A	0
2025-05-19	MRKR	1.12	N/A	N/A	0
2025-05-20	MRKR	1.136	N/A	N/A	0
2025-05-21	MRKR	1.1	N/A	N/A	0
2025-05-22	MRKR	1.12	N/A	N/A	0
2025-05-23	MRKR	1.135	N/A	N/A	0
2025-05-27	MRKR	1.15	N/A	N/A	0
2025-05-28	MRKR	1.115	N/A	N/A	0
2025-05-29	MRKR	1.21	N/A	N/A	0
2025-05-30	MRKR	1.51	N/A	N/A	0
2025-06-02	MRKR	1.41	N/A	N/A	0
2025-06-03	MRKR	1.52	N/A	N/A	0
2025-06-04	MRKR	1.51	N/A	N/A	0
2025-06-05	MRKR	1.505	N/A	N/A	0
2025-06-06	MRKR	1.77	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-05-08	MRKR	1.28	-18.5	-	-1.29
2025-05-09	MRKR	1.16	-18.5	-	-1.29
2025-05-12	MRKR	1.14	-18.5	-	-1.29
2025-05-13	MRKR	1.14	-18.5	-	-1.29
2025-05-14	MRKR	1.12	-18.5	-	-1.29
2025-05-15	MRKR	1.12	-18.5	-	-1.29
2025-05-16	MRKR	1.10	-18.5	-	-1.29
2025-05-19	MRKR	1.13	-	-	-1.29
2025-05-20	MRKR	1.14	-	-	-1.29
2025-05-21	MRKR	1.12	-	-	-1.29
2025-05-22	MRKR	1.13	-	-	-1.29
2025-05-23	MRKR	1.13	-	-	-1.29
2025-05-27	MRKR	1.15	-8.0	-	-1.19
2025-05-28	MRKR	1.11	-8.0	-	-1.19
2025-05-29	MRKR	1.21	-8.0	-	-1.19
2025-05-30	MRKR	1.56	-8.0	-	-1.19
2025-06-02	MRKR	1.42	-8.0	-	-1.19
2025-06-03	MRKR	1.52	-8.0	-	-1.19
2025-06-04	MRKR	1.51	-8.0	-	-1.19
2025-06-05	MRKR	1.52	-8.0	-	-1.19
2025-06-06	MRKR	1.77	-8.0	-	-1.19
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-05-08	MRKR	19.81	2.45	2.50
2025-05-09	MRKR	19.82	2.45	2.50
2025-05-12	MRKR	19.83	2.46	1.60
2025-05-13	MRKR	19.83	2.46	1.60
2025-05-14	MRKR	19.81	2.46	1.60
2025-05-15	MRKR	19.81	2.46	1.60
2025-05-16	MRKR	19.82	2.46	1.60
2025-05-19	MRKR	19.82	2.42	1.60
2025-05-20	MRKR	19.82	2.42	1.60
2025-05-21	MRKR	19.81	2.42	1.60
2025-05-22	MRKR	19.81	2.42	1.60
2025-05-23	MRKR	19.81	2.42	1.60
2025-05-27	MRKR	19.81	10.37	1.60
2025-05-28	MRKR	19.81	10.37	1.61
2025-05-29	MRKR	19.82	10.37	1.61
2025-05-30	MRKR	19.81	10.37	1.61
2025-06-02	MRKR	19.82	10.37	1.61
2025-06-03	MRKR	19.82	10.37	1.61
2025-06-04	MRKR	19.82	10.37	1.61
2025-06-05	MRKR	19.81	10.37	1.61
2025-06-06	MRKR	19.81	10.37	1.61
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

19.81

Institutional Transactions

10.37

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

95.3

Max Drawdown 5-Year %

-98

Target Price

8.17

P/E

Forward P/E

PEG

P/S

3.51

P/B

1.37

P/Free Cash Flow

EPS

-1.33

Average EPS Est. Cur. Y

-1.19

EPS Next Y. (Est.)

-0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-224.45

Relative Volume

1.46

Return on Equity vs Sector %

-81.9

Return on Equity vs Industry %

-63.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.1

EBIT Estimation

Marker Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 5

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

stock quote shares MRKR – Marker Therapeutics Inc Stock Price stock today

news today MRKR – Marker Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MRKR – Marker Therapeutics Inc yahoo finance google finance

stock history MRKR – Marker Therapeutics Inc invest stock market

stock prices MRKR premarket after hours

ticker MRKR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRKR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y